{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:51:18Z","timestamp":1793404278862,"version":"4.5.0"},"reference-count":28,"publisher":"American Society of Tropical Medicine and Hygiene","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,2,5]]},"abstract":"<jats:p>Cutaneous leishmaniasis (CL) and mucocutaneous leishmaniasis (MCL) are endemic diseases in America, especially in some countries such as Colombia. Among the therapeutic options is amphotericin B (AB). Nevertheless, its lipid-associated formulations have better safety profiles and effectiveness in other diseases, so far with no comparative studies in CL or MCL. We conducted a retrospective descriptive study describing the effectiveness and adverse effects of AB deoxycholate (ABD), AB colloidal dispersion (ABCD), and liposomal AB (LAB) as third-line treatments for CL and MCL. The effectiveness of LAB (88.5%) was greater than those of ABCD (66.6%) and ABD (80.8%). There were also fewer adverse effects in the LAB group (46.2%) than in the ABD (96.1%) and ABCD (80.9%) groups. LAB is an alternative for the treatment of CL and MCL in patients with therapeutic failure to first- and second-line drugs; findings suggest it might be less toxic and more effective than ABD and ABCD.<\/jats:p>","DOI":"10.4269\/ajtmh.18-0514","type":"journal-article","created":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T07:01:02Z","timestamp":1575961262000},"page":"274-279","source":"Crossref","is-referenced-by-count":17,"title":["Effectiveness and Safety of Amphotericin B Deoxycholate, Amphotericin B Colloidal Dispersion, and Liposomal Amphotericin B as Third-Line Treatments for Cutaneous and Mucocutaneous Leishmaniasis: A Retrospective Study"],"prefix":"10.4269","volume":"102","author":[{"given":"Mar\u00eda Claudia","family":"Rodr\u00edguez Galvis","sequence":"first","affiliation":[{"name":"Central Military Hospital, Bogota, Colombia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jairo Enrique","family":"P\u00e9rez Franco","sequence":"additional","affiliation":[{"name":"Central Military Hospital, Bogota, Colombia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirian Yolanda","family":"Casas Vargas","sequence":"additional","affiliation":[{"name":"Nueva Granada Military University (Universidad Militar Nueva Granada), Bogota, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Fernanda","family":"Ordo\u00f1ez Rubiano","sequence":"additional","affiliation":[{"name":"Central Military Hospital, Bogota, Colombia;"},{"name":"Nueva Granada Military University (Universidad Militar Nueva Granada), Bogota, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2795","reference":[{"key":"b1","series-title":"Eur J Dermatol","first-page":"115","article-title":"Immunology of cutaneous leishmaniasis: the role of mast cells, phagocytes and dendritic cells for protective immunity","volume":"17","author":"Von Stebut","year":"2007"},{"key":"b2","series-title":"Int J Infect Dis","first-page":"e525","article-title":"Recent advances in leishmaniasis treatment","volume":"15","author":"Tiuman","year":"2011"},{"key":"b3","series-title":"Clin Infect Dis","first-page":"1","article-title":"Clinical spectrum of leishmaniasis","volume":"22","author":"Pearson","year":"1996"},{"key":"b4","series-title":"Dermatol Clin","first-page":"579","article-title":"New World and Old World leishmania infections","volume":"33","author":"Kevric","year":"2015"},{"key":"b5","series-title":"Control of Leishmaniasis: Report of a Meeting of the WHO Expert Committee on the Control of Leishmaniasis","first-page":"200","author":"World Health Organization","year":"2012"},{"key":"b6","series-title":"J Infect Dis","first-page":"1846","article-title":"Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis","volume":"195","author":"Arevalo","year":"2007"},{"key":"b7","series-title":"PLoS Negl Trop Dis","first-page":"e0004739","article-title":"Clinical and parasitological features of patients with American cutaneous leishmaniasis that did not respond to treatment with meglumine antimoniate","volume":"10","author":"Perez-Franco","year":"2016"},{"key":"b8","series-title":"Comprehensive Care Guide for Leishmaniasis 2010","author":"Pan American Health Organization PAHO\/WHO, Colombia Ministry of Social Protection","year":"2010"},{"key":"b9","series-title":"Leishmaniasis in the Americas. Recommendations for the Treatment; 2013","author":"World Health Organization\/PanAmerican Health Organization","year":"2013"},{"key":"b10","series-title":"Biom\u00e9dica","first-page":"3","article-title":"Susceptibility of clinical strains of Leishmania to pentavalent antimony and miltefosine: challenges and opportunities","volume":"31","author":"Saravia","year":"2011"},{"key":"b11","series-title":"Clin Microbiol Rev","first-page":"111","article-title":"Drug resistance in leishmaniasis","volume":"19","author":"Croft","year":"2006"},{"key":"b12","series-title":"J Infect Dis","first-page":"1375","article-title":"Resistance to antimony and treatment failure in human Leishmania (Viannia) infection","volume":"193","author":"Rojas","year":"2006"},{"key":"b13","series-title":"Int J Dermatol","first-page":"109","article-title":"Treatment of New World cutaneous leishmaniasis\u2013a systematic review with a meta-analysis","volume":"47","author":"Tuon","year":"2008"},{"key":"b14","series-title":"Expert Opin Pharmacother","first-page":"53","article-title":"Leishmaniasis: an update of current pharmacotherapy","volume":"14","author":"Sundar","year":"2013"},{"key":"b15","series-title":"Am J Trop Med Hyg","first-page":"1028","article-title":"Lipsosomal amphotericin B for treatment of cutaneous leishmaniasis","volume":"83","author":"Wortmann","year":"2010"},{"key":"b16","series-title":"Drugs","first-page":"919","article-title":"Amphotericin B formulations: a comparative review of efficacy and toxicity","volume":"73","author":"Hamill","year":"2013"},{"key":"b17","series-title":"Expert Opin Emerg Drugs","first-page":"493","article-title":"Liposomal amphotericin B as a treatment for human leishmaniasis","volume":"17","author":"Balasegaram","year":"2012"},{"key":"b18","series-title":"Am J Trop Med Hyg","first-page":"1214","article-title":"Efficacy and safety of liposomal amphotericin B for the treatment of mucosal leishmaniasis from the new world: a retrospective study","volume":"93","author":"Cunha","year":"2015"},{"key":"b19","series-title":"Epidemiological report of the americas. Leishmaniases","author":"Pan American Health Organization","year":"2017"},{"key":"b20","series-title":"Rev Chil Infectol","first-page":"518","article-title":"Formas lip\u00eddicas de anfotericina [Lipid forms of amphotericin]","volume":"31","author":"Botero","year":"2014"},{"key":"b21","series-title":"J Infect Dev Ctries","first-page":"961","article-title":"Diagnosis of leishmaniasis","volume":"8","author":"Elmahallawy","year":"2014"},{"key":"b22","series-title":"Expert Opin Pharmacother","first-page":"475","article-title":"Amphotericin B colloidal dispersion","volume":"1","author":"Patel","year":"2000"},{"key":"b23","series-title":"Antimicrob Agents Chemother","first-page":"e02009","article-title":"AmBisome\u00ae treatment of murine cutaneous leishmaniasis: relation between skin pharmacokinetics and efficacy","volume":"62","author":"Wijnant","year":"2018"},{"key":"b24","series-title":"Antimicrob Agents Chemother","first-page":"1031","article-title":"Mechanism of amphotericin B resistance in clinical isolates of Leishmania donovani","volume":"56","author":"Purkait","year":"2012"},{"key":"b25","series-title":"Antimicrob Agents Chemother","first-page":"3274","article-title":"Production and characterization of stable amphotericin-resistant amastigotes and promastigotes of Leishmania mexicana","volume":"49","author":"Al-Mohammed","year":"2005"},{"key":"b26","series-title":"PLoS Negl Trop Dis","first-page":"e0006094","article-title":"Liposomal amphotericin B in travelers with cutaneous and muco-cutaneous leishmaniasis: not a panacea","volume":"20","author":"Guery","year":"2017"},{"key":"b27","series-title":"Drug Resistance in Leishmania Parasites: Consequences, Molecular Mechanisms and Possible Treatments","author":"Ponte-Sucre","year":"2013"},{"key":"b28","series-title":"Am J Infect Control","first-page":"S1","article-title":"Guidelines for the prevention of intravascular catheter-related infections","volume":"39","author":"O\u2019Grady","year":"2011"}],"container-title":["The American Journal of Tropical Medicine and Hygiene"],"original-title":[],"link":[{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/102\/2\/article-p274.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/102\/2\/article-p274.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/102\/2\/article-p274.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T21:57:29Z","timestamp":1722463049000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/102\/2\/article-p274.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,5]]},"references-count":28,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.4269\/ajtmh.18-0514","relation":{},"ISSN":["0002-9637","1476-1645"],"issn-type":[{"value":"0002-9637","type":"print"},{"value":"1476-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,5]]}}}